Umoja Biopharma
Umoja Biopharma focuses on innovative immunotherapy by reprogramming T cells within the patient's body to target cancer effectively. The company offers scalable therapeutic regimens designed for solid tumors and hematological cancers that typically respond poorly to current treatments. Its in-house CAR T-cell gene therapy platform aims toimprove patient outcomes across various stages of cancer.
$100M
Latest Funding
Series C
Latest Funding Stage
2025-01-20
Funding Date
195
Employees
United States
Location
Seattle, Washington
City & State
Key Contacts
Open Positions
View Careers PageHiring For
Similar Startups
Archipelo
The Archipelo Developer Security Posture Management Platform provides organizations with—the underlying system of record to capture SDLC event data tied to developer actions. Archipelo empowers security, GRC, and engineering teams to proactively identify, triage, and mitigate risks before they impact your business.
Workhelix
Workhelix brings together advanced research and comprehensive data to assess organizations' generative AI opportunities and which tasks can be accelerated with available technology, enabling businesses to navigate the opportunity landscape with data and reports, rather than relying on gut and instinct.
Eikon Therapeutics
Eikon Therapeutics is a biopharmaceutical company that focuses on developing innovative technologies for drug discovery. The company utilizes advanced live-cell resolution microscopy and engineering to identify and create new therapeutic candidates. Eikon Therapeutics aims to enhance the understanding of biological processes at a cellular level,supporting targeted treatment development.
Mimic
Mimic Networks is a cybersecurity company that provides an enterprise ransomware defense platform for security teams. The company's platform detects, deflects, and facilitates rapid recovery from ransomware attacks, aiming to serve as the last line of defense to ensure that critical data remains secure against increasingly sophisticatedcyberthreats.